Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead of continuing intensive chemotherapy either shrunk tumors or stopped them from growing in 17 of 19 patients in an interim analysis from a trial at the Abramson Cancer Center at the University of Pennsylvania.![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
↧